Response to Comments: Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers

This LCD (L39806) addresses coverage of skin substitute grafts and other cellular and tissue‑based products for diabetic foot ulcers and venous leg ulcers, with public comments from 04/25/24–06/08/24 reviewed and addressed in the response article. The response article specifies the detailed coverage versus exclusions and any clinical/documentation requirements that will govern the LCD (notice begins 11/14/24; effective 02/12/25).